Home News & Events Events Event Archive

Past Events

Jefferies 2017 Global Healthcare Conference

The conference will feature an extensive range of public & private healthcare companies across the Biopharmaceuticals, Life Sciences, Healthcare Services, Healthcare IT and Medical Technology sectors. This global gathering of leading executives, institutional investors, private equity investors and VCs will address near- and long-term investment opportunities and discuss the mechanisms driving healthcare in the U.S. and internationally.

6 - 9, June, 2017, New York City, USA

ASCO 2017 Annual Meeting

2 - 6, June, 2017, Chicago, USA

Key Opinion Leader Meeting

Kiadis Pharma will host a Key Opinion Leader meeting on the topic of ‘Addressing the Risks of Haploidentical HSCT in Blood Cancer’ on Wednesday, May 31 from 12:00pm – 1:30pm Eastern Time in New York City.

This lunch event is intended for institutional investors, sell-side analysts, investment bankers and business development professionals only. Please RSVP in advance if you plan to attend, as space is limited. To reserve a spot, please contact LifeSci Advisors, LLC at Mac@LifeSciAdvisors.com. A live and archived webcast of the event, with slides, will be available on the Company’s website and http://lifesci.rampard.com/20170531/reg.jsp.

31, May, 2017, New York, USA

25th International Society of Cellular Therapy (ISCT)

Kiadis Pharma’s abstract has been selected by the International Society for Cellular Therapy (ISCT) as a Late Breaking Abstract for an oral presentation at the 2017 Annual Meeting in London, United Kingdom on May 4, 2017.

The abstract provides key clinical data from the Company’s international multi-center trial on the improvement of event-free survival (GRFS) and overall survival in patients treated with ATIR101™ as part of their transplant regimen. The last update on this trial was presented at the ASH meeting in December 2016. The abstract will be presented by Dr. Halvard Bönig, Professor for Translational Development of Cellular Therapeutics at the Johann-Wolfgang-Goethe University and Head of the Department of Cellular Therapeutics / Cell Processing (GMP) of the German Red Cross Blood Donor Service, Baden-Wuerttemberg-Hessen, which manufactures the Company’s lead product ATIR101™ for Europe.

Date: Thursday May 4, 2017 between 15:30 and 17:00 BST
Abstract title: Add back of selectively depleted alloreactive T-cells retaining the full immune repertoire of mature T-cells improves event-free survival (GRFS) and overall survival in a T-cell depleted haploidentical HSCT
Presenting author: Dr. Halvard Bönig
Abstract number: LB01
Location: ExCeL London

The abstract can be viewed here. In addition, the abstract will be published in the online version of Cytotherapy, the official journal of ISCT.

3 - 6, May, 2017, London, United Kingdom

43rd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)

The abstracts providing information on the design of the Company’s recently initiated Phase III clinical trial with lead product ATIR101™ and Phase I/II clinical trial with ATIR201™, have been accepted for poster presentation on March 27 and 28, 2017 respectively at the 43rd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Marseille, France.

Poster presentations:
Date:Monday March 27, 2017 from 9:00 – 18:30 CET
Title: Introduction of the HATCY study: A Phase III, multicenter, randomized controlled study to compare safety and efficacy of a haploidentical HSCT and adjunctive treatment with ATIR101 with post-transplant cyclophosphamide in patients with a hematologic malignancy
Poster: A171
You can find the abstract here.

Date: Tuesday March 28, 2017 from 9:00 – 18:00 CET
Title: An exploratory, open-label study to evaluate the safety and feasibility of ATIR201, a T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells (using photodynamic treatment), as adjuvant treatment to a T-cell depleted haploidentical hematopoietic stem cell transplantation in patients with beta-thalassemia major
Poster: B276
You can find the abstract here.

Full abstracts are also available on the EBMT website. In addition, the abstracts will be published in the supplement edition of Bone Marrow Transplantation.

26 - 29, March, 2017, Marseille, France

Kiadis Pharma Satellite Symposium at the EBMT 2017 – Advances in Haploidentical Stem Cell Transplantation and Post-Transplant Immunotherapy

Kiadis Pharma will host a satellite symposium on March 26, 2017 entitled: “Advances in Haploidentical Stem Cell Transplantation and Post-Transplant Immunotherapy”. The symposium will be chaired by Dr. Hermann Einsele, Professor at the University Hospital of the Julius-Maximilians-University, Würzburg, Germany and he will be joined by several other international key opinion leaders in the field of hematopoietic stem cell transplantation. The symposium will provide an update on recent developments in haploidentical stem cell transplantation, including post-transplant Cyclophosphamide, T-cell depletion methodologies and use of immunotherapy approaches after transplantation, such as ATIR101™. Presentations will be given by Prof. Arnon Nagler of the Chaim Sheba Medical Center, Tel-Hashomer, Israel; Prof. Leo Luznik of the Johns Hopkins University School of Medicine, Baltimore, USA; Prof. Stephan Mielke of the University Hospital, Würzburg, Germany; and Prof. Denis-Claude Roy of the Maisonneuve-Rosemont Hospital, Montreal, Canada.

Date: Sunday March 26, 2017 from 11.00 – 12.30 CET
Room: Les Goudes 2
Title: Advances in Haploidentical Stem Cell Transplantation and Post-Transplant Immunotherapy

The full program can be viewed here, and is also available on http://www.ebmt2017.org/kiadis

26 - 26, March, 2017, Marseille, France

58th ASH (American Society of Hematology) Annual Meeting

Data from the Company’s ongoing Phase II clinical trial (NCT01794299/EudraCT 2012-004461-41) with its lead product ATIR101™ has been selected by the American Society of Hematology (ASH) Program Committee for an oral presentation at the 58th Annual Meeting in San Diego, California on December 5, 2016.

The abstract will be presented by Dr. Denis-Claude Roy, Professor of Medicine at the University of Montreal and one of the principal investigators for the trial, and will provide one year data from Kiadis Pharma’s international multi-center study, in which a total of 23 leukemia patients, including patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS), have been enrolled to be treated with ATIR101™ as part of their transplant regimen. In addition, the abstract includes a comparison to a historic control group.

Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Improve Event-Free Survival (GRFS) and Overall Survival in a T-Cell Depleted Haploidentical HSCT: Phase 2 Trial in Patients with AML and ALL (Abstract #1226)
San Diego Convention Center, Room 30, session 711: Cell Collection and Processing: Immunotherapy, Immunomodulation and Immune Reconstitution

Monday, December 5, 2016 from 6:15 to 7:45 PM Eastern Daylight Time (EDT) (presentation time: 6:30 PM EDT)

Click here to read the full abstract.

The presentation is now available for download using the Download button below.

3 - 6, December, 2016, San Diago (CA), USA

22nd Annual Meeting of the International Society for Cellular Therapy (ISCT)

The ISCT is a global society of clinicians, regulators, technologists and industry partners with a shared vision to translate cellular therapy into safe and effective therapies to improve patients’ lives. The scientific program includes symposia, educational sessions and workshops covering the key issues relating to cell therapy. Read more on www.isct2016.com

Kiadis Pharma has four abstracts that have been accepted for presentation at the International Society for Cellular Therapy (ISCT) 2016 Annual Meeting on May 25-28, 2016 in Singapore.

In addition, Jurjen Velthuis, the Company’s Vice-President CMC, gave a presentation on ‘Defining critical process parameters’ during the Session “Quality and Operations Track 5 – CMC Process Characterization and Parameters”.

See below the abstract of the oral presentation and the abstracts of the three poster presentations (including the posters):

Phase II clinical trial of Allodepleted T-cell Immunotherapy (ATIR101) post-transplant results in decreased transplantrelated mortality and improved survival in acute leukemia patients undergoing T-depleted haploidentical stem cell transplantation”. See Abstract.

Selective depletion of alloreactive T-cells while retaining virus-specific and memory T-cells from haploidentical donor lymphocytes”. See Abstract and Poster (P188).

Leukemia-associated antigen reactive T-cells in ATIR101, a recipient-specific allodepleted T-cell product t0 reduce relapse rates and GVHD after haplo-HSCT”. See Abstract and Poster (P189).

Application of Quality by Design in allogeneic cell-based therapy processes and assay development”. See Abstract and Poster (P238).

25 - 28, May, 2016, Singapore

CBMTG 2016 Annual Conference

Kiadis Pharma attended the Annual Conference of the Canadian Blood and Marrow Transplant Group (CBMTG).

See below the abstract and poster presentation:

“Post-transplant administration of donor lymphocytes depleted of alloreactive T-cells (ATIR101) improves overall survival and reduces transplant related mortality following T-cell depleted haploidentical HSCT: Results from a Phase 2 Trial in patients with AML and ALLL”.
See abstract and poster.

24 - 27, April, 2016, Vancouver, Canada

42nd Annual Meeting of the European Society for Blood and Marrow Transplantation

The EBMT Annual Meeting is the most important annual event for research and education in the field of bone marrow transplantation in Europe. The scientific programme includes symposia, educational sessions and workshops covering the key issues relating to bone marrow and stem cell transplantation. Read more on www.ebmt.org.

See below the abstract of the oral presentation and three poster presentations, including submitted abstracts:

“Donor lymphocytes depleted of alloreactive T-cells (ATIR101) improve overall survival and reduce transplant related mortality in a T-cell depleted haploidentical HSCT: Results from a Phase 2 Trial in patients with AML and ALL”. See Abstract (#O042).

Leukemia-associated antigen reactive T-cells in ATIR101, a recipient-specific allodepleted T-cell product facilitating haploidentical HSCT”. See Abstract and Poster (#P0020).

Effect of graft source on safety and efficacy in patients undergoing hematopoietic stem cell transplantation”. See Abstract and Poster (#P442).

An exploratory, open-label, multicenter study to evaluate safety and efficacy of a two-dose regimen of ATIR101 in patients with a hematologic malignancy, who received a CD34-selected hematopoietic stem cell transplantation from a haploidentical donor”. See Abstract and Poster (#P462).

3 - 6, April, 2016, Valencia, Spain

Kiadis Pharma hosted Webcast on Monday April 4, 2016 at 18.00 hrs CET

Kiadis Pharma hosted Webcast on Monday April 4, 2016 at 18.00 hrs CET: Full dataset on the primary endpoint of its single dose phase II trial with ATIR101™

If you were unable to dial into the webcast “Top-line data on the primary endpoint of Kiadis Pharma’s Phase II trial with ATIR101™” please use the following link to access the replay: Please register here

Please use the link below to download the presentation of this webcast as a PDF.

 

4, April, 2016, Valencia, Spain

57th ASH (American Society of Hematology) Annual Meeting

The Annual Meeting of the American Society of Hematology (ASH) is the world’s premier event in malignant & non-malignant hematology. Kiadis Pharma presented an update on its Phase II trial with ATIR101™ at this meeting. The poster used in the presentation is available for download.

5 - 8, December, 2015, Orlando (FL), USA